Corona Remedies shares rose sharply on December 15, extending gains after a blockbuster IPO debut. Strong institutional demand, consistent profitability and a focused chronic therapy portfolio have supported post-listing momentum, even as the stock trades at rich valuations, keeping investors watchful of execution and margin sustainability.